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INTRODUCTION
A temporal decline in gastric cancer (GC) incidence 
has been seen in several countries, including Brazil[1,2]. 
However, this cancer causes nearly one million deaths 
a year worldwide and is still a serious public health 
cancer[3], especially in the Pará State, Northern Brazil, 
where mortality rates are higher than the national 
average rate[2]. GC is usually diagnosed at advanced 
stages and the single curative therapy available requires 
surgical resection[4]. 
Over 95% of  gastric malignancies are adenocarcino-
mas[5]. They are subdivided into two main histological 
types: well-differentiated or intestinal-type, and 
undifferentiated or diffuse-type[6]. Intestinal-type gastric 
tumors predominate in high-risk geographic areas 
whereas diffuse-type tumors are more common in low-
risk areas[7]. 
The identification of  peculiar genetic characteristics of  
gastric tumors may help predict prognosis of  GC patients 
and allow more accurate therapeutic approaches. Genetic 
analyses of  GC suggest that there occur structural 
and functional alterations of  several oncogenes and 
tumor suppressor genes, as well as genetic instability[8]. 
Additionally, GC has been an interesting carcinogenesis 
model. Evidence suggests that intestinal- and diffuse-
type gastric carcinomas develop through distinct genetic 
pathways due to different genetic alterations identified in 
these histological types[9,10]. 
MYC (C-MYC) oncogene has been described as a key 
element of  several carcinogenesis processes in humans[11]. 
In the present review, we focus on the deregulation of  the 
MYC oncogene in gastric carcinogenesis. 
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Abstract
MYC is an oncogene involved in cell cycle regulation, 
cell growth arrest, cell adhesion, metabolism, ribosome 
biogenesis, protein synthesis, and mitochondrial 
function. It has been described as a key element of 
several carcinogenesis processes in humans. Many 
studies have shown an association between MYC 
deregulation and gastric cancer. MYC deregulation is 
also seen in gastric preneoplastic lesions and thus it 
may have a role in early gastric carcinogenesis. Several 
studies have suggested that amplification is the main 
mechanism of MYC deregulation in gastric cancer. 
In the present review, we focus on the deregulation 
of the MYC oncogene in gastric adenocarcinoma 
carc inogenesis, inc luding i ts associat ion with 
Helicobacter pylori  (H pylori ) and clinical applications. 
© 2008 The WJG Press. All rights reserved.
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MYC AND CANCER 
MYC gene was found to be the cellular homolog of  
retroviral v-myc oncogene about 30 years ago[12-14]. It is 
located on chromosomal region 8q24.1, has 3 exons[15,16] 
and encodes a nuclear phosphoprotein[17]. 
MYC has to heteromerize with MAX, a protein 
expressed constitutively, to acquire DNA-binding 
activity. MYC/MAX dimmers are made viable by a basic 
region helix-loop-helix leucine-zipper motif  (bHLH-
Zip), conserved sequences in the carboxyl terminus 
of  both proteins. MYC/MAX dimmers bind to E-box 
sequence CACGTG in the promoters of  specific target 
genes and stimulate their transcription[18]. 
MYC has an effect on up to about 15% of  genes in 
genomes of  many organisms, from flies to humans[19]. 
Groups of  genes involved in cell cycle regulation, 
metabolism, ribosome biogenesis, protein synthesis, and 
mitochondrial function are over-represented in the Myc 
target gene network. 
MYC also consistently represses genes involved in 
cell growth arrest and cell adhesion[20]. Dominguez-Sola 
et al[21] recently showed that Myc interacts with the pre-
replicative complex and localizes to early sites of  DNA 
synthesis. Thus, it also has a direct role in the control of  
DNA replication. 
MYC regulates transcription from its targets through 
several mechanisms, including recruitment of  histone 
acetylases, chromatin modulating proteins, basal 
transcription factors and DNA methyltransferase[22-26]. 
Protein products of  MYC target genes go on 
to mediate the downstream effects of  MYC on cell 
biology. MYC is then rapidly degraded, and the pathway 
switches to a transcriptionally repressive state when 
MAX dimerizes with a group of  related bHLH-Zip 
proteins, the MAD family, that act as MYC antagonists[27] 
(Figure 1). 
MYC expression might be regulated transcriptionally 
(initiation and elongation), post-transcriptionally (mRNA 
stability and translation) or post-translationally (protein 
stability)[28]. 
MYC is generally recognized as an important regulator 
of  proliferation, growth, differentiation and apoptosis[29,30]. 
Therefore, it is also accepted that the deregulation of  
MYC expression is a major event in cancer pathogenesis 
or progression. Deregulated expression of  a wild-type 
MYC protein is sufficient to lead to cellular transformation 
in vitro and tumorigenesis in vivo[31]. 
Recen t s t ud i e s have a l so found tha t MYC 
oncoprotein, in addition to its directly transforming 
role, can mediate genomic instability via the induction 
of  reactive oxygen species and by promoting whole 
chromosome instability leading to tetraploidy and 
aneuploidy. MYC’s ability to promote chromosomal 
instabi l i ty i s c losely l inked to i ts funct ion as a 
transcriptional regulator[32]. Our research group reported 
higher frequency of  tetraploid clones in GC cell line[33] 
and aneuploid cells in primary gastric tumor[34,35]. 
Oncogenic alterations of  MYC are commonly induced 
by events such as point mutations, gene amplification, 
chromosomal translocation, viral insertion at the MYC 
locus, and resistance of  MYC protein to ubiquitin-
mediated proteolysis and enhanced transcription or 
translation by other oncogenic signaling pathways[30]. 
MYC AND GASTRIC CARCINOGENESIS 
MYC overexpression has been described in over 40% 
of  GC[36]. We found that MYC protein was expressed 
in all cases of  both intestinal- and diffuse-type gastric 
adenocarcinoma samples of  individuals from Northern 
Brazil[37]. Table 1[38-59] shows the proportion of  cases with 
MYC aberration in several GC studies. 
Several studies have shown the association between 
MYC expression and histopathologic characteristics. Xu 
et al[51] and Yang et al[54] described a significantly higher 
expression of  MYC in intestinal-type than in diffuse-
type GC. 
Kozma et al[50] and Yang et al[54] reported that higher 
MYC expression was associated with the presence of  
metastasis. Onoda et al[41] also found MYC mRNA levels 
were higher in metastatic than in primary lesions. Han 
et al[45] described that patients with high levels of  MYC 
expression had poor disease-free survival. Therefore, 
MYC expression may represent an aggressive phenotype 
of  GC. 
MYC overexpression has also been seen in early 
GC when tumor invasion is confined to the mucosa or 
submucosa regardless of  the presence of  lymph node 
metastasis[40,41,45,46,52,54,59]. Yang et al[54] found a significantly 
higher expression of  MYC in advanced GC than in early 
stage GC. However, Onoda et al[41] reported that MYC 
expression was found to be more frequent and stronger 
in early than in advanced lesions. Other studies have not 
found this same difference. 
Several studies demonstrated an increased MYC 
expression in pre-cancerous gastric lesions and its 
increased expression also has been associated with 
Helicobacter pylori (H pylori) infection. H pylori is defined as 
a carcinogen factor to gastric carcinoma infection by the 
International Agency for Research on Cancer (IARC)[60]. 
Figure 1  Activation of MYC target genes by the interaction between MYC:MAX 
or their repression by MAX:MAD. Domains that are common to each protein 
and are involved in heterodimerization are shown; b: Basic region; HLH: Helix-
loop-helix; LZ: Leucine zipper. E-box sequence is shown in green.
b HLH  LZ
b HLH  LZ
MAX
MYC
MAX
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Chronic gastritis caused by H pylori infection may 
progress to intestinal metaplasia and even to GC[61,62]. 
Tatsuta et al[63] evaluated MYC mRNA expression 
by in situ hybridization in 31 elevated gastric lesions. 
Patients who had borderline lesions with and without 
MYC overexpression were followed up with repeated 
endoscopic examinations and gastric biopsies. The 
authors reported that well-differentiated elevated-type 
adenocarcinomas were detected in 46% of  patients with 
elevated lesions that presented MYC overexpression 
during a follow-up period of  about 15 mo (range, 
2-32 mo) and that no cancers were found in patients 
with elevated lesions without MYC overexpression. 
These sample groups were significantly different. 
Therefore, MYC overexpression may provide a valuable 
tool for distinguishing between adenomas and well-
differentiated elevated-type adenocarcinomas. 
Xu et al[51] noticed that MYC protein expression 
increased progressively as follows: chronic active gastritis, 
gastric ulcer, mild nonclassic proliferation, severe non-
classic proliferation, early GC, and progressive GC. 
Lan et al[53] found that MYC expression was higher 
in GC than in chronic gastritis, intestinal metaplasia 
and dysplasia. MYC expression was higher in type Ⅲ 
intestinal metaplasia with H pylori compared to the 
same metaplasia without infection and the positive 
rate in dysplasia with H pylori was higher than that 
without infection. Zhang et al[55] also reported that MYC 
expression was higher in chronic atrophic gastritis 
with severe intestinal metaplasia than that with mild 
intestinal metaplasia. In chronic atrophic gastritis with 
severe intestinal metaplasia, MYC expression was higher 
in cases with H pylori infection than in those without 
infection. Higher MYC expression was also found in GC 
with H pylori infection than in that without infection. 
Thus, MYC expression was coordinately up-regulated in 
H pylori infected GC and chronic atrophic gastritis with 
severe intestinal metaplasia. Authors have suggested that 
H pylori infection may affect MYC expression in gastric 
diseases, especially in chronic atrophic gastritis. 
Several studies have shown that patients with 
preneoplastic and neoplastic gastric epithelial lesions 
are more likely to be infected by cagA positive strains. 
H pylori cagA is one of  the most virulent strains of  H pylori. 
Increased cancer risk is described in individuals infected 
by cagA-positive H pylori strains compared with those 
infected by cagA-negative H pylori strains and, in general, 
in those living in areas with a high rate of  cagA-positive 
H pylori strains[64]. Yang et al[54] compared MYC expression 
in gastric tissues (intestinal metaplasia, dysplasia and GC) 
with and without H pylori cagA. These authors found that 
MYC expression was significantly higher in those lesions 
of  type Ⅲ intestinal metaplasia and dysplasia Ⅱ-Ⅲ 
with cagA than in those without cagA. Nardone et al[64] 
also suggested that the increased prevalence of  MYC 
expression was in agreement with the high prevalence of  
cagA positivity seen in the population studied. 
Kim et al[65] investigated the expression of  MYC 
protein and mRNA in 22 patients with chronic gastritis 
who had been successfully treated for H pylori. Two 
endoscopic antral biopsies were taken before and 
2 mo after H pylori eradication. The proportion of  
gastric antral epithelial cells expressing MYC protein 
was significantly lower after H pylori eradication. 
MYC mRNA expression was not changed by H pylori 
eradication. H pylori may affect cell cycle progression 
and carcinogenesis through post-translational effects on 
specific gene expression. Nardone et al[64] also found that 
MYC expression disappeared after H pylori eradication. 
In vitro studies have also confirmed that H pylori can 
Table 1  Several MYC studies in gastric cancer
Reference Cause of MYC deregulation Increased MYC Number of cases Rate (%) of cases with MYC deregulation 
[38] Overexpression Protein   88                                  55
[39] Overexpression Protein 213                                  23.5
[40] Amplification/Overexpression DNA/Protein   31/51                                  12.9/41.2 
[41] Overexpression RNA   51                                  68.6
[42] Amplification DNA   23                                  26
[43] Amplification DNA   21                                  48
[44] Amplification Protein 154                                  15.5
[45] Overexpression Protein   48 advanced/28 early                                  50/42 
[46] Overexpression Protein   98 advanced/45 early                                  28/34 
[47] Amplification DNA   51                                  24
[48] Amplification DNA   10                                  30
[49] Overexpression Protein   42 advanced/77 early                                  40.5/15.6 
[50] Amplification/Overexpression DNA/Protein   23                                  26
[51] Overexpression Protein   30 advanced/ 6 early                                  63.3/50 
[52] Overexpression Protein   35 advanced/74 early                                  34/16 
[53] Overexpression Protein   84                                  88.1
[54] Overexpression Protein   63                                  52.4
[55] Overexpression Protein   65                                  61.5
[56] Amplification DNA/Protein   11                                100
[37] Amplification/Overexpression DNA/Protein     7                                100
[57] Overexpression Protein 204                                  43
[58] Overexpression Protein   71                                  42.3
[59] Amplification/Overexpression DNA/Protein     5 early                                100
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affect MYC expression. Yang et al[66] described that H pylori 
induces apoptosis in human gastric adenocarcinoma cells 
mediated by an increased expression of  MYC mRNA. 
Epstein-Barr virus (EBV) is another infectious agent 
thought to contribute to cancerous transformation of  
human host cells. EBV infection is seen in about 10% 
of  gastric adenocarcinoma cases[49,58,67]. Ishii et al[49] 
found MYC expression in early stages of  EBV-positive 
GC was higher than that of  EBV-negative GC, while 
MYC expression in advanced stages of  EBV-positive 
GC was lower than that of  EBV-negative tumors. It was 
inferred that EBV might cause the host cell to induce 
MYC expression in early cancer development, but then 
negatively affect MYC expression in advanced stages 
of  cancers, making them less likely to have a natural 
regression via apoptosis. Lima et al[58] also reported MYC 
low expression in EBV-positive GC samples. However, 
Luo et al[67] have not found any correlation between EBV 
and MYC expression in GC, suggesting that EBV does 
not inhibit MYC expression in advanced stages of  EBV-
positive gastric cancer. 
MECHANISMS OF MYC DEREGULATION 
IN GASTRIC CANCER 
Copy number gains are frequently detected along 
chromosome 8 in gastric tumors[43,48,56,68-73]. Suzuki 
et al[43] described that chromosome 8 copy number was 
significantly higher in differentiated than undifferentiated 
types of  GC. Our research group found 8q24.1 gain, 
where MYC is located, exclusively in intestinal subtype 
with metastasis by comparative genome hybridization 
(CGH) [72]. However, Koo e t a l [48] repor ted that 
amplifications in 8q region were more common in diffuse-
type cancer. 
Some studies have showed an association between 
MYC amplif ication and GC[42-44,48]. We have also 
previously seen MYC amplification in intestinal 
adenocarcinoma by dual-color fluorescence in situ 
hybridization (FISH), such as homogeneously staining 
chromosomal regions and double minutes, supporting 
our CGH results[56]. Our findings support that these two 
histological GC types follow different genetic pathways. 
Our research group also found that all five early GC 
cases with MYC overexpression also had three signal to 
MYC gene by FISH assay, varying between 13% and 26% 
of  cells/case[59]. Suzuki et al[43] found MYC amplification 
in all 6 early GC cases studied, varying between 19% 
and 89% of  cells/case, and this rate was not significantly 
difference from that found in advanced GC samples. 
These findings suggest that MYC amplification can be a 
critical event to gastric carcinogenesis. 
MYC translocation is frequently described in Burkitt’s 
lymphoma. Few studies have also found translocation 
of  the MYC locus associated with gastric carcinogenesis. 
Yamashita et al[74] identified chromosomal translocations 
involved in 8q24 breakpoint by spectral karyotyping 
(SKY) analysis of  established GC cel l l ines and 
cancerous ascitic fluids. In a previous study, our findings 
suggested that translocations can be related to diffuse-
type GC using FISH assay[37,56].  
Epigenetic events play a significant role in cancer 
development and progression. DNA methylation is the 
most studied epigenetic alteration. Some studies also 
have demonstrated that MYC hypomethylation, which 
leads to its activation, is significantly more common in 
GC samples than non-cancerous tissues[75,76]. Fang et al[77] 
and Weng et al[78] suggest that folate level reduction is 
associated with upregulation of  MYC expression and its 
promoter hypomethylation in GC. 
FUTURE PERSPECTIVES 
Proto-oncogenes have a major role not only in cancer 
development, but also in cancer therapies[79]. MYC 
alteration is seen in the early gastric carcinogenesis 
progress. The detection of  MYC locus amplification may 
be used as an auxiliary tool to GC diagnosis and as a 
predictor of  GC aggressiveness. 
MYC also could be used as a therapeutical target. 
Several experimental studies showed that MYC inactivation 
suppresses tumors in animal models, suggesting MYC as a 
molecular target in cancer treatment[80-83]. 
Chen et al[84] evaluated the effect of  MYC expression 
inhibition by recombinant antisense MYC adenovirus 
(Ad-ASc-myc) infected SGC7901 human gastric 
carcinoma cells, which have MYC gene amplification, 
in the proliferation, apoptosis and growth processes 
of  human gastric tumors in nude mice. It was found 
that MYC expression inhibition may strongly inhibit 
cell growth and induce apoptosis in SGC7901 cells. 
Proliferation of  Ad-ASc-myc-infected SGC7901 cells 
was reduced by 44.1%. Studies involving tumorigenicity 
in nude mice and experimental therapy in nude 
mice model using Ad-ASc-myc also support these 
findings. These studies also suggest that Ad-ASc-myc 
overexpression may result in the elimination of  tumor 
cells via apoptosis and proliferation inhibition, and 
therefore reduce tumor burden. 
Inhibiting MYC expression can be a potential tool 
for GC treatment in tumors with MYC overexpression. 
MYC’s therapy target may help identifying more specific 
and less toxic therapeutic agents[30].  
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